On December 4, 2024, Michael Constantino, a Director at Humacyte Inc (HUMA, Financial), purchased 4,600 shares of the company, according to a SEC Filing. This transaction brings the insider's total ownership to 16,950 shares.
Humacyte Inc is a biotechnology company focused on developing bioengineered human tissue for use in regenerative medicine and vascular surgery. The company's innovative approach aims to improve patient outcomes by providing off-the-shelf, bioengineered tissues that can be used in a variety of medical applications.
The recent purchase by Michael Constantino is part of a broader trend of insider activity at Humacyte Inc. Over the past year, the insider has acquired a total of 7,700 shares and has not sold any shares. In the same period, the company has seen 12 insider buys and 13 insider sells.
Shares of Humacyte Inc were trading at $4.39 each on the day of the purchase, resulting in a market cap of $570.002 million for the company. Investors often monitor insider buying and selling as potential indicators of a company's future performance.
For more information on Humacyte Inc's valuation metrics, such as the GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can refer to the respective links.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
